Summary.-Walker carcinosarcoma cells cause in vitro osteolysis which may be inhibited by aspirin. In the rat, this tumour produces osteolytic bone deposits and hypercalcaemia, both of which can be prevented by aspirin and indomethacin, whereas soft tissue tumour deposits are unaffected by these drugs. Some human breast tumours cause in vitro osteolysis which may be inhibited by aspirin.
PATIENTS with breast cancer frequently develop abnormalities in their calcium metabolism, which are usually associated with osteolytic bone metastases (Galasko and Burn, 1971) and are caused by excessive mobilization of calcium from the skeleton. This raises the possibility that the mechanism for this skeletal calcium mobilization, and the ability of tumour deposits to develop into destructive bone deposits, may both depend on the ability of tumour cells to produce osteolytic substances.
To investigate this hypothesis, we have used an in vitro organ culture system of neonatal mouse bone which releases calcium in response to known osteolytic substances. We have found that some, but not all, human breast carcinomata when added to the organ culture caused increased calcium release from the bones and that this osteolysis could be inhibited by aspirin.
To test whether these in vitro observations were relevant to the in vivo behaviour of tumours, it was necessary to develop a suitable animal tumour model. For this, we chose the intra-aortic injection of Walker carcinosarcoma cells into the rat, because this tumour has been reported to cause hypercalcaemia (Raue et al., 1972) Aspirin was introduced into the culture system by dissolving pure acetyl salicylic acid in Bigger's medium and diluting to the required concentration.
The pH of the medium was measured at the beginning and the end of the 3 day culture period for all cultures.
In vivo animal tumour system.-In preliminary experiments on rats we found that intra-aortic injection of Walker tumour cells resulted in the development of soft tissue and lytic bone tumour deposits in the legs, and also hypercalcaemia. To test whether antiosteolytic agents, effective in vitro, could influence the development of destructive bone deposits and hypercalcaemia, we performed 3 experiments injecting 103 Walker cells (as a single cell suspension in 0-2 ml of medium 199) into the abdominal aorta of 120 g male Wistar rats. The animals in each experiment were divided into 2 groups; a test group in which the animals were force fed daily with aspirin and indomethacin dissolved in water, and a control group force fed with an equal volume of water. Most of the pharmacological actions of aspirin are similar to those of indomethacin, and therefore to test for any in vivo anti-osteolytic activity by aspirin it was decided to use aspirin with indomethacin in these experiments to achieve maximum aspirin-like effect.
In Experiments I and II the test animals were given 30 mg of aspirin and 041 mg of indomethacin per day, commencing 3 days before tumour cell administration. After 10 days the drug dosages were doubled. In Experiment III, the test animals were given 60 mg of aspirin and 0-2 mg of indomethacin per day, commencing 7 days after tumour cell administration. The animals were sacrificed by decapitation 14 days after tumour cell administration, blood samples collected and the serum calcium levels determined by the routine clinical autoanalytical method. The extent of soft tissue tumour was evaluated at post mortem examination by weighing the legs and subtracting the weights of legs from control non-tumour bearing animals of the same body weight. The number of osteolytic bone deposits were evaluated by x-ray examination of the legs, the x-ray plates being coded and assessed independently by 2 observers. Obvious destructive bone deposits occurred in the legs only at the lower end of the femur and the upper end of the tibia and each bone either had an obvious destructive lesion or not, making a possible total number of bone deposits for each animal of 0, 1, 2, 3, or 4.
RESULTS

In vitro experiments
Some, but not all, human breast tumours caused marked increases in the release of 45Ca from the labelled bones in culture. Three of these active tumours were also tested for activity in the presence of aspirin (16 ,ag/ml) and found to be significantly inhibited by this drug (Table I ). The depression of pH of the the bones in culture and aspirin (16 ,tg/ml) significantly inhibited this release (Table  II) . Indomethacin (2 jtg/ml) gave a similar inhibition of calcium release. This concentration of aspirin appeared to have no detectable effect on the metabolism or viability of the tumour cells as assessed by dye exclusion, phase contrast microscopy and acid production.
Reduction of the pH of the medium by the addition of lactic acid also produced increased 45Ca release (Table III) (Table IV) , and therefore acid production by tumour cells must be taken into account when evaluating the total osteolytic effect of these cells in vitro. This may be done by using a " correction " curve for the pH effect of lactic acid and comparing this with the 45Ca release caused by Walker cells in relation to the pH change caused by the cells. For 2 concentrations of Walker cells this is represented graphically in Fig. 1 In vivo experinments In Experiment I, 8 rats were treated with aspirin and indomethacin and 8 rats used as control. All animals in both groups developed clinically obvious soft tissue tumours in the legs on the 10th or 11th day after tumour cell injection, and when all the animals were sacrificed on the 14th day there was no significant difference in the amount of soft tissue tumours in the control and treated groups.
However, although all but one of the control animals had obvious destructive tumour deposits in the bones of the legs and 2 animals were hypercalcaemic, none of the treated animals had any detectable bone deposits and none were hypercalcaemic (Table V) . In Experiment II, comprising 21 animals, the tumours in the soft tissues became clinically obvious rather earlier than in Experiment I and by Day 14, when the animals were sacrificed, there was more soft tissue tumour. Again, there was no significant inhibition of growth of soft tissue tumour in the treated compared with the control group.
However, although all the control group animals had widespread bone deposits, none of the treated animals had detectable bone deposits and the hypercalcaemia which had developed in all but one of the control animals was prevented in all the treated animals (Table VI) . In Experiment III, in which administration of (Table  VII) . (Weissmann, 1968) or to decrease the release of lysosomal enzymes from some types of intact cells (Wright and Malawista, 1971), Miller and Smith (1966) Another possible inhibitory mechanism of aspirin may involve its ability to inhibit prostaglandin synthesis (Vane, 1971) . Prostaglandins have been shown to cause in vitro osteolysis (Klein and Raisz, 1970) and may also be responsible for the in vitro osteolytic properties of a mouse fibrosarcoma (Tashjian et al., 1972) . The production of prostaglandin E2 and the in vitro osteolysis caused by this tumour were both inhibited by indomethacin.
It has been shown that some human breast tumours possess in vitro osteolytic properties which may be significantly inhibited by aspirin, and it is possible that the abnormalities in calcium metabolism in patients with breast cancer may depend on production of osteolytic sub-stance by the tumour which may also facilitate the growth of metastases in bone. Aspirin may therefore be effective in the prevention of hypercalcaemia and bone metastases. Accordingly, we are currently evaluating the effect of aspirin on the calcium metabolism of patients with breast cancer and its influence on the development of bone metastases inpatients whose primary tumours are osteolytically active.
